These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 17611572)

  • 61. Population pharmacokinetics of busulfan in children--letter.
    Nguyen L; Paci A; Vassal G
    Clin Cancer Res; 2012 May; 18(9):2715-6; author reply 2717-8. PubMed ID: 22553376
    [No Abstract]   [Full Text] [Related]  

  • 62. Incompatibility of busulfan with 1 ml Luer-Lock syringes.
    Loboda C; Lider P; Vigneron J
    J Oncol Pharm Pract; 2016 Jun; 22(3):571-2. PubMed ID: 26424711
    [No Abstract]   [Full Text] [Related]  

  • 63. Disseminated scotochromogen infection and unusual myeloproliferative disorder. Report of a case and review of the literature.
    McNutt DR; Fudenberg HH
    Ann Intern Med; 1971 Nov; 75(5):737-44. PubMed ID: 5287449
    [No Abstract]   [Full Text] [Related]  

  • 64. A study of 51 Cr-labelled platelets and the chromosomal pattern in a case of primary haemorrhagic thrombocythaemia.
    Wiik AS; Paulson OB; Sorensen CM; Visfeldt J
    Acta Haematol; 1971; 46(3):177-87. PubMed ID: 5001521
    [No Abstract]   [Full Text] [Related]  

  • 65. "Allopurinol-type" rash due to busulphan.
    Leyden MJ; Manoharan A
    Lancet; 1978 Oct; 2(8093):797. PubMed ID: 80726
    [No Abstract]   [Full Text] [Related]  

  • 66. Clinical trial of busulfan (NSC-750) in advanced carcinoma of prostate.
    Arduino LJ; Mellinger GT
    Cancer Chemother Rep; 1967 Sep; 51(5):295-303. PubMed ID: 4863188
    [No Abstract]   [Full Text] [Related]  

  • 67. [Case of megakaryocyte leukemia with an unusual course].
    Droszcz W; Mdzewski B; Wrońska J; Porembińska H; Jedrzejewski R; Bogacka-Zatorska H
    Pol Arch Med Wewn; 1978 Oct; 60(4):367-72. PubMed ID: 568780
    [No Abstract]   [Full Text] [Related]  

  • 68. [Efficacy of pipobroman in the treatment of essential thrombocythemia].
    Bauters F; Jouet JP; Simon M; Pollet JP; Fenaux P; Walter MP
    Presse Med; 1988 Jan; 17(2):81. PubMed ID: 2964031
    [No Abstract]   [Full Text] [Related]  

  • 69. HEMORRHAGIC THROMBOCYTHEMIA: REPORT OF A CASE.
    HALL WJ
    JAMA; 1965 Jun; 192():912-4. PubMed ID: 14298143
    [No Abstract]   [Full Text] [Related]  

  • 70. [CONTRIBUTION TO THE CLINICAL PICTURE OF HEMORRHAGIC THROMBOCYTHEMIA].
    OHLER WG; FRIEDERICI L; CASTENHOLZ A
    Med Welt; 1965 May; 19():1034-7. PubMed ID: 14304413
    [No Abstract]   [Full Text] [Related]  

  • 71. Treatment of acute megakaryocytic leukemia.
    Ann Intern Med; 1986 Feb; 104(2):280-1. PubMed ID: 3946965
    [No Abstract]   [Full Text] [Related]  

  • 72. Radiosensitization after busulphan.
    Vassal G; Hartmann O; Habrand JL; Pico JL; Lemerle J
    Lancet; 1987 Mar; 1(8532):571. PubMed ID: 2881122
    [No Abstract]   [Full Text] [Related]  

  • 73. No convulsions in children on high-dose busulphan.
    Hugh-Jones K; Shaw PJ
    Lancet; 1985 Jan; 1(8422):220. PubMed ID: 2857291
    [No Abstract]   [Full Text] [Related]  

  • 74. Essential thrombocythemia: Busulphan revisited.
    Koduri PR
    Indian J Med Paediatr Oncol; 2016; 37(2):123. PubMed ID: 27168714
    [No Abstract]   [Full Text] [Related]  

  • 75. Developing strategies to reduce the duration of therapy for patients with myeloproliferative neoplasms.
    Bar-Natan M; Hoffman R
    Expert Rev Hematol; 2020 Nov; 13(11):1253-1264. PubMed ID: 33012187
    [TBL] [Abstract][Full Text] [Related]  

  • 76. MPN: The Molecular Drivers of Disease Initiation, Progression and Transformation and their Effect on Treatment.
    Grabek J; Straube J; Bywater M; Lane SW
    Cells; 2020 Aug; 9(8):. PubMed ID: 32823933
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Ruxolitinib for the Treatment of Essential Thrombocythemia.
    Gunawan A; Harrington P; Garcia-Curto N; McLornan D; Radia D; Harrison C
    Hemasphere; 2018 Aug; 2(4):e56. PubMed ID: 31723782
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: "2019 Update on Diagnosis, Risk-stratification, and Management".
    Patnaik MM; Tefferi A
    Am J Hematol; 2019 Apr; 94(4):475-488. PubMed ID: 30618061
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Essential thrombocythemia treatment algorithm 2018.
    Tefferi A; Vannucchi AM; Barbui T
    Blood Cancer J; 2018 Jan; 8(1):2. PubMed ID: 29321520
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T): 2017 update on diagnosis, risk-stratification, and management.
    Patnaik MM; Tefferi A
    Am J Hematol; 2017 Mar; 92(3):297-310. PubMed ID: 28188970
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.